那他珠单抗治疗多发性硬化。
Natalizumab therapy for multiple sclerosis.
机构信息
Queen Square Multiple Sclerosis Centre, National Hospital for Neurology & Neurosurgery and University College London Institute of Neurology, Queen Square, London, WC1N 3BG, UK.
出版信息
Neurotherapeutics. 2013 Jan;10(1):19-28. doi: 10.1007/s13311-012-0171-4.
Abstract
The treatment of relapsing remitting multiple sclerosis has witnessed major progress since the first effective disease modifying treatment, ß-interferon, became available in 1993. One of the most remarkable new treatments has been natalizumab. This review describes the evolution of this humanized anti-α4ß1 monoclonal antibody, from preclinical experimental research through proof-of-concept (phase 1/2) and pivotal (phase 3) clinical trials to the now extensive experience of its use in clinical practice. The future potential and challenges of natalizumab and oral therapies with a similar mechanism of action are also discussed.
摘要
自 1993 年首个有效的疾病修正治疗药物——β干扰素问世以来，复发性缓解型多发性硬化症的治疗取得了重大进展。其中最显著的新疗法之一是那他珠单抗。本文描述了这种人源化抗 α4β1 单克隆抗体的发展历程，从临床前实验研究到概念验证（1/2 期）和关键（3 期）临床试验，再到目前在临床实践中的广泛应用。本文还讨论了那他珠单抗的未来潜力和挑战，以及具有类似作用机制的口服疗法。
相似文献
1
Natalizumab therapy for multiple sclerosis.那他珠单抗治疗多发性硬化。
Neurotherapeutics. 2013 Jan;10(1):19-28. doi: 10.1007/s13311-012-0171-4.
2
Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study.在复发缓解型多发性硬化症中，与那他珠单抗、芬戈莫德和干扰素β相比，阿仑单抗的治疗效果：一项队列研究。
Lancet Neurol. 2017 Apr;16(4):271-281. doi: 10.1016/S1474-4422(17)30007-8. Epub 2017 Feb 11.
3
Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.用于多发性硬化症的免疫调节剂和免疫抑制剂：一项网状Meta分析
Cochrane Database Syst Rev. 2013 Jun 6;2013(6):CD008933. doi: 10.1002/14651858.CD008933.pub2.
4
Update on disease-modifying treatments for multiple sclerosis.多发性硬化症疾病修正治疗的最新进展。
Clin Ther. 2014 Dec 1;36(12):1938-1945. doi: 10.1016/j.clinthera.2014.08.006. Epub 2014 Sep 15.
5
Natalizumab is effective as second line therapy in the treatment of relapsing remitting multiple sclerosis.那他珠单抗作为二线治疗药物，在复发缓解型多发性硬化症的治疗中疗效显著。
Eur J Neurol. 2009 Mar;16(3):424-6. doi: 10.1111/j.1468-1331.2008.02519.x.
6
How effective is natalizumab as second-line treatment for multiple sclerosis in daily clinical praxis?在日常临床实践中，那他珠单抗作为多发性硬化症的二线治疗药物效果如何？
Eur J Neurol. 2009 Mar;16(3):287-8. doi: 10.1111/j.1468-1331.2008.02518.x.
7
Immunomodulatory therapies for relapsing-remitting multiple sclerosis: monoclonal antibodies, currently approved and in testing.复发缓解型多发性硬化症的免疫调节疗法：单克隆抗体，目前已获批及正在测试的情况。
Expert Rev Clin Pharmacol. 2015 May;8(3):283-96. doi: 10.1586/17512433.2015.1036030.
8
Spanish consensus on the use of natalizumab (Tysabri®)-2013.2013年西班牙那他珠单抗（泰萨比®）使用共识
Neurologia. 2015 Jun;30(5):302-14. doi: 10.1016/j.nrl.2013.10.004. Epub 2013 Dec 19.
9
Natalizumab vs interferon beta 1a in relapsing-remitting multiple sclerosis: a head-to-head retrospective study.那他珠单抗与干扰素β 1a 治疗复发缓解型多发性硬化症的头对头回顾性研究。
Acta Neurol Scand. 2012 Nov;126(5):306-14. doi: 10.1111/j.1600-0404.2011.01622.x. Epub 2011 Nov 23.
10
Effectiveness of natalizumab in patients with highly active relapsing remitting multiple sclerosis.那他珠单抗治疗高度活动性复发缓解型多发性硬化症患者的疗效
Eur Neurol. 2015;73(3-4):220-229. doi: 10.1159/000375371. Epub 2015 Mar 13.
引用本文的文献
1
The novel HS-mimetic, Tet-29, regulates immune cell trafficking across barriers of the CNS during inflammation.新型 HS 模拟物 Tet-29 在炎症期间调节免疫细胞穿越中枢神经系统屏障的迁移。
J Neuroinflammation. 2023 Nov 1;20(1):251. doi: 10.1186/s12974-023-02925-4.
2
Endothelial Cell Insulin Signaling Regulates CXCR4 (C-X-C Motif Chemokine Receptor 4) and Limits Leukocyte Adhesion to Endothelium.内皮细胞胰岛素信号调节 CXCR4（C-X-C 基序趋化因子受体 4）并限制白细胞与内皮细胞的黏附。
Arterioscler Thromb Vasc Biol. 2022 Jul;42(7):e217-e227. doi: 10.1161/ATVBAHA.122.317476. Epub 2022 Jun 2.
3
Multiple Sclerosis: Focus on Extracellular and Artificial Vesicles, Nanoparticles as Potential Therapeutic Approaches.多发性硬化症：关注细胞外和人工囊泡、纳米颗粒作为潜在的治疗方法。
Int J Mol Sci. 2021 Aug 18;22(16):8866. doi: 10.3390/ijms22168866.
4
Gray matter atrophy in multiple sclerosis despite clinical and lesion stability during natalizumab treatment.尽管在那他珠单抗治疗期间临床和病变稳定，但多发性硬化症仍存在灰质萎缩。
PLoS One. 2018 Dec 21;13(12):e0209326. doi: 10.1371/journal.pone.0209326. eCollection 2018.
5
Natalizumab-Related Progressive Multifocal Leukoencephalopathy-Immune Reconstitution Inflammatory Syndrome: A Case Report Highlighting Clinical and MRI Features.那他珠单抗相关的进行性多灶性白质脑病-免疫重建炎症综合征：一例突出临床和MRI特征的病例报告
Malays J Med Sci. 2016 Sep;23(5):91-95. doi: 10.21315/mjms2016.23.5.12. Epub 2016 Oct 5.
6
Serum Gelatinases Levels in Multiple Sclerosis Patients during 21 Months of Natalizumab Therapy.那他珠单抗治疗21个月期间多发性硬化症患者的血清明胶酶水平
Dis Markers. 2016;2016:8434209. doi: 10.1155/2016/8434209. Epub 2016 Jun 2.
7
[Monitoring of blood parameters under course-modified MS therapy : Substance-specific relevance and current recommendations for action].[病程修正型多发性硬化症治疗期间的血液参数监测：物质特异性相关性及当前行动建议]
Nervenarzt. 2016 Jun;87(6):645-59. doi: 10.1007/s00115-016-0077-1.
8
Epstein-Barr Virus Specific Antibody Response in Multiple Sclerosis Patients during 21 Months of Natalizumab Treatment.纳他珠单抗治疗21个月期间多发性硬化症患者的爱泼斯坦-巴尔病毒特异性抗体反应
Dis Markers. 2015;2015:901312. doi: 10.1155/2015/901312. Epub 2015 May 26.
9
The efficacy and safety of daclizumab and its potential role in the treatment of multiple sclerosis.达克珠单抗的疗效与安全性及其在多发性硬化治疗中的潜在作用。
Ther Adv Neurol Disord. 2014 Jan;7(1):7-21. doi: 10.1177/1756285613504021.
10
Defining and scoring response to IFN-β in multiple sclerosis.多发性硬化症中干扰素-β反应的定义和评分。
Nat Rev Neurol. 2013 Sep;9(9):504-12. doi: 10.1038/nrneurol.2013.146. Epub 2013 Jul 30.
本文引用的文献
1
Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy.磁共振成像在那他珠单抗相关性进行性多灶性白质脑病中的表现。
Ann Neurol. 2012 Nov;72(5):779-87. doi: 10.1002/ana.23676.
2
Risk of natalizumab-associated progressive multifocal leukoencephalopathy.纳武利尤单抗相关进行性多灶性白质脑病的风险。
N Engl J Med. 2012 May 17;366(20):1870-80. doi: 10.1056/NEJMoa1107829.
3
Value of MRI as a surrogate marker for PML in natalizumab long-term therapy.磁共振成像（MRI）作为那他珠单抗长期治疗中进行性多灶性白质脑病（PML）替代标志物的价值。
J Neurol. 2012 Aug;259(8):1732-3. doi: 10.1007/s00415-012-6426-5.
4
Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoring.那他珠单抗相关的进行性多灶性白质脑病：风险评估与监测的实用方法
Pract Neurol. 2012 Feb;12(1):25-35. doi: 10.1136/practneurol-2011-000092.
5
Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial.非奈利特治疗复发缓解型多发性硬化症：一项 2 期、随机、双盲、安慰剂对照试验。
Lancet Neurol. 2012 Feb;11(2):131-9. doi: 10.1016/S1474-4422(11)70299-X. Epub 2012 Jan 5.
6
Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1.多发性硬化症患者中抗约翰·坎宁安病毒抗体的流行率：STRATIFY-1 的基线结果。
Ann Neurol. 2011 Nov;70(5):742-50. doi: 10.1002/ana.22606.
7
The clinical features of PML.PML 的临床特征。
Cleve Clin J Med. 2011 Nov;78 Suppl 2:S8-12. doi: 10.3949/ccjm.78.s2.03.
8
Herpes encephalitis during natalizumab treatment in multiple sclerosis.多发性硬化症患者在接受那他珠单抗治疗时发生疱疹性脑炎。
Mult Scler. 2012 Jun;18(6):909-11. doi: 10.1177/1352458511428082. Epub 2011 Nov 2.
9
Natalizumab for relapsing remitting multiple sclerosis.那他珠单抗用于复发缓解型多发性硬化症。
Cochrane Database Syst Rev. 2011 Oct 5(10):CD007621. doi: 10.1002/14651858.CD007621.pub2.
10
Immune reconstitution inflammatory syndrome in natalizumab-associated PML.与纳武单抗相关的进行性多灶性白质脑病中的免疫重建炎症综合征。
Neurology. 2011 Sep 13;77(11):1061-7. doi: 10.1212/WNL.0b013e31822e55e7. Epub 2011 Aug 10.
Zotero 插件